Selective Triple Negative Breast Cancer Therapy
A compound that selectively decreases chemoresistance in triple negative tumours and other highly aggressive metastatic malignancies
- U.S. Granted patent US10,201,610 B2 entitled “Interference Peptides and Use Thereof”. Other iPeps against transcription factors have also been protected/are being developed.
- Patent application submitted
- Development partner